机构：[1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, number 1291, Jiangning road, Putuo, Shanghai 200060, China.[2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, number 301, Middle Yanchang road, Jing’an, Shanghai 200072, China.[3]Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.[4]Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China.[5]Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China.
Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75-85% of primary liver cancers, and sorafenib is the first targeted drug for advanced HCC treatment. However, sorafenib resistance is common because of the resultant enhancement of aerobic glycolysis and other molecular mechanisms. Aerobic glycolysis was firstly found in HCC, acts as a hallmark of liver cancer and is responsible for the regulation of proliferation, immune evasion, invasion, metastasis, angiogenesis, and drug resistance in HCC. The three rate-limiting enzymes in the glycolytic pathway, including hexokinase 2 (HK2), phosphofructokinase 1 (PFK1), and pyruvate kinases type M2 (PKM2) play an important role in the regulation of aerobic glycolysis in HCC and can be regulated by many mechanisms, such as the AMPK, PI3K/Akt pathway, HIF-1 alpha, c-Myc and noncoding RNAs. Because of the importance of aerobic glycolysis in the progression of HCC, targeting key factors in its pathway such as the inhibition of HK2, PFK or PKM2, represent potential new therapeutic approaches for the treatment of HCC.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670472]; Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [19ZR1447700]; Health System Innovation Project of Shanghai Putuo Science and Technology Commission [PTKWWS201801, PTKWWS201903]; WBN Hepatology Research Fund of China Hepatitis Prevention and Treatment Foundation [CFHPC2019031]
第一作者机构：[1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, number 1291, Jiangning road, Putuo, Shanghai 200060, China.[2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, number 301, Middle Yanchang road, Jing’an, Shanghai 200072, China.
通讯作者：
通讯机构：[1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, number 1291, Jiangning road, Putuo, Shanghai 200060, China.[2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, number 301, Middle Yanchang road, Jing’an, Shanghai 200072, China.[3]Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.[4]Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China.[5]Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China.
推荐引用方式(GB/T 7714)：
Feng Jiao,Li Jingjing,Wu Liwei,et al.Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J].JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH.2020,39(1):doi:10.1186/s13046-020-01629-4.
APA：
Feng, Jiao,Li, Jingjing,Wu, Liwei,Yu, Qiang,Ji, Jie...&Guo, Chuanyong.(2020).Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,39,(1)
MLA：
Feng, Jiao,et al."Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma".JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 39..1(2020)
医学